Test could 'revolutionize' TB care and control
Source: Agencies |
December 9, 2010, Thursday
|
Print Edition
Print Edition
THE World Health Organization (WHO) gave its backing yesterday to a new molecular test for tuberculosis (TB) made by Cepheid which can rapidly diagnose TB, one of the world's biggest killer diseases.
The WHO said in a statement it was endorsing the test because it could "revolutionize" TB care and control by accurately diagnosing patients in about 100 minutes, compared to current tests that can take up to three months to give results.
Cepheid said it would offer a 75 percent price discount for poorer nations on the tests and the table top computer system used to analyze them, meaning the tests will cost US$16.86 and the machine will cost around US$17,000.
The firm's chief executive, John Bishop, said this preferential price would be granted to 116 low-and middle-income countries where TB is endemic, and prices would be discounted further as the volume of demand rises in coming years.
The test, called Xpert MTB/RIF, was developed by Cepheid and the Foundation for Innovative and New Diagnostics (FIND), a non-profit group funded by the Bill & Melinda Gates Foundation, the European Union and national donors. It detects many TB cases missed by current technology, which is more than a century old.
"There has been a strong commitment to remove any obstacles, including financial barriers, that could prevent the successful roll-out of this new technology," said Giorgio Roscigno, FIND's chief executive. "For the first time in TB control, we are enabling access to state-of-the-art technology simultaneously in low, middle and high income countries."
TB hits mostly poor people in developing regions such as sub-Saharan Africa, India and China, but also occurs in poor regions of developed nations and is common in patients with the human immunodeficiency virus (HIV) that causes AIDS.
It is among the world's top 10 leading causes of death. The WHO estimates that 9.4 million people developed active TB in 2009 and it killed 1.7 million in that year. The emergence of drug-resistant and extensively drug-resistant forms of TB is also a growing global problem.
The WHO said implementation of this test could result in a three-fold increase in the diagnosis of patients with drug-resistant TB and a doubling in the number of HIV-associated TB cases diagnosed in areas with high rates of TB and HIV.
Mario Raviglione, director of the WHO's Stop TB department said the test represented "a major milestone" for TB care.
The Xpert system can also be used to diagnose a number of other illnesses, including flu, leukemia, sexually transmitted infections, and the so-called "superbug" MRSA.
The WHO said in a statement it was endorsing the test because it could "revolutionize" TB care and control by accurately diagnosing patients in about 100 minutes, compared to current tests that can take up to three months to give results.
Cepheid said it would offer a 75 percent price discount for poorer nations on the tests and the table top computer system used to analyze them, meaning the tests will cost US$16.86 and the machine will cost around US$17,000.
The firm's chief executive, John Bishop, said this preferential price would be granted to 116 low-and middle-income countries where TB is endemic, and prices would be discounted further as the volume of demand rises in coming years.
The test, called Xpert MTB/RIF, was developed by Cepheid and the Foundation for Innovative and New Diagnostics (FIND), a non-profit group funded by the Bill & Melinda Gates Foundation, the European Union and national donors. It detects many TB cases missed by current technology, which is more than a century old.
"There has been a strong commitment to remove any obstacles, including financial barriers, that could prevent the successful roll-out of this new technology," said Giorgio Roscigno, FIND's chief executive. "For the first time in TB control, we are enabling access to state-of-the-art technology simultaneously in low, middle and high income countries."
TB hits mostly poor people in developing regions such as sub-Saharan Africa, India and China, but also occurs in poor regions of developed nations and is common in patients with the human immunodeficiency virus (HIV) that causes AIDS.
It is among the world's top 10 leading causes of death. The WHO estimates that 9.4 million people developed active TB in 2009 and it killed 1.7 million in that year. The emergence of drug-resistant and extensively drug-resistant forms of TB is also a growing global problem.
The WHO said implementation of this test could result in a three-fold increase in the diagnosis of patients with drug-resistant TB and a doubling in the number of HIV-associated TB cases diagnosed in areas with high rates of TB and HIV.
Mario Raviglione, director of the WHO's Stop TB department said the test represented "a major milestone" for TB care.
The Xpert system can also be used to diagnose a number of other illnesses, including flu, leukemia, sexually transmitted infections, and the so-called "superbug" MRSA.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
